GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference


GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference

CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall


https://ca.finance.yahoo.com/news/genspera-present-rodman-renshaw-16th-120000029.html

SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ — GenSpera, Inc. (GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

The conference is attended by public companies, institutional investors, sophisticated private investors and industry executives.

GenSpera will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss the significance of the recently announced HCC clinical trial update for G-202, its lead drug candidate, as well as provide a corporate overview. The company has released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib ( Nexavar®, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary). Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study. In addition, imaging analysis demonstrated impressive blockade of tumor blood flow in the single patient evaluated by this method to date.

Hepatocellular carcinoma (HCC) is currently the sixth most common malignancy in the world and the third leading cause of cancer-related mortality worldwide.

Craig Dionne, PhD, GenSpera’s CEO said of the pending conference,” I am excited to share the recent data and results for G-202 and its efficacy and safety analyses on patients to date. G-202 has potential to treat multiple cancers including prostate cancer and glioblastoma but our primary focus is currently hepatocellular carcinoma (HCC). The liver cancer data we recently presented at APPLE and other scientific conferences was overwhelmingly embraced by our peers; now this conference creates an opportunity to explain the significance and the promise it holds to the investment community.”

About the conference:
http://www.rodm.com/

About GenSpera

GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company’s website: http://www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at:
http://www.genspera.com/

Watch the Corporate Video:
http://youtu.be/jULjEul-mBk

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s